For research use only. Not for therapeutic Use.
Zanubrutinib（Cat No.:I014765）is a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor used primarily in the treatment of B-cell malignancies, such as mantle cell lymphoma and chronic lymphocytic leukemia. By targeting BTK, zanubrutinib blocks critical signaling pathways essential for the growth and survival of malignant B cells, thereby inhibiting cancer progression. Its improved selectivity over earlier BTK inhibitors helps to minimize off-target effects and enhances therapeutic efficacy. Zanubrutinib has shown promising results in clinical trials, providing a valuable option in the treatment of certain hematologic cancers.
| Catalog Number | I014765 |
| CAS Number | 1691249-45-2 |
| Synonyms | (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
| Molecular Formula | C27H29N5O3 |
| Purity | 97% |
| Target | BTK |
| Target Protein | Q06187 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | BTK IC50: 1.8nM |
| IUPAC Name | (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
| InChI | InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1 |
| InChIKey | RNOAOAWBMHREKO-QFIPXVFZSA-N |
| SMILES | C=CC(=O)N1CCC(CC1)[C@@H]2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N |
| Reference | [1]. Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res 2015;75(15 Suppl):Abstract nr 2597. [2]. Guo Y, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem. 2019 Sep 12;62(17):7923-7940. |
